… in EGFR-mutated advanced NSCLC. Therefore, to properly addressed this problem, we
designed this randomized, phase-2 study comparing the efficacy and tolerability of erlotinib 100 …

… conducted a randomized phase 2 study to explore the clinical benefits of adding pemetrexed
to gefitinib in patients with advanced … The primary analysis of this study showed a significant …

… study. Methods: This was a multicenter (17 centers in China) phase II randomized controlled
trial of erlotinib… as neoadjuvant/adjuvant therapy in pts with stage IIIA-N2 NSCLC with EGFR …

… , randomized, placebo-controlled phase 2 study 26 on advanced NSCLC after two lines of
… Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review …

… a multicenter, randomized phase IB/II study performed in two countries, Spain and Mexico.
Eligible patients were 18 years or older, treatment-naïve, pathologically confirmed stage IV …

… study aimed to investigate the efficacy and safety of preoperative gefitinib in patients with
stage II-IIIA operable non–small … whereas patients were enrolled with stage II or IIIA in our study…

… randomized phase 2 trial has compared erlotinib + RT and CCRT in patients with EGFRm-positive
unresectable stage … In a phase 2 study by Lee et al, 12 which compared E + RT versus …

… chemotherapy) trials, 12 erlotinib potentially prolonged the 5-year DFS in the … study
population compared with gefitinib. Another recent phase II study of adjuvant erlotinib for patients …

… First-line gefitinib for patients with advanced non–small-cell lung cancer harboring …
multicenter phase 2 clinical trial to investigate the efficacy and safety of low-dose erlotinib in …

… In conclusion, gefitinib as postoperative adjuvant therapy for patients with resected stage
II-III NSCLC harboring EGFR mutations was not beneficial in prolonging DFS and OS. Thus, …